Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study

Abstract

To compare the prevalence of cardiovascular disease (CVD) and major CVD risk factors among rheumatoid arthritis (RA) patients enrolled in a large US and multinational registry. We compared CVD and CVD risk factor prevalence from 11 countries enrolled in the CORRONA US and CORRONA International registries; patients from the 10 ex-US participating countries were grouped by region (Eastern Europe, Latin America, and India). Unadjusted summary data were presented for demographics and disease characteristics; comparisons for prevalence of CVD risk factors and CVD were age/gender standardized to the age/gender distribution of the US enrolled patients. Overall, 25,987 patients were included in this analysis. Compared to patients from the ex-US regions, US participants had longer disease duration and lower disease activity, yet were more likely to receive a biologic agent. Additionally, CORRONA US participants had the highest body mass index (BMI). Enrolled patients in India had the lowest BMI, were more rarely smokers, and had a low prevalence of hyperlipidemia, hypertension, and prior CVD compared to the US and other ex-US regions. Participants from Eastern Europe had a higher prevalence of hypertension and hyperlipidemia and highest prevalence of all manifestations of CVD. Differences in the prevalence of both CVD and major CVD risk factors were observed across the four regions investigated. Observed differences may be influenced by variations in both non-modifiable/modifiable characteristics of patient populations, and may contribute to heterogeneity on the observed safety of investigational and approved therapies in studies involving RA patients from different origins.

Incident arterial vascular events in a cohort of Puerto Ricans with rheumatoid arthritis

“… 25 Interestingly, in the CORRONA study, the prevalence of hypertension (39.4%), dyslipidemia (18.6%), and DM (8.4%) in Latin Americans with cardiovascular events appears to be much lower than that reported for our population. 13 This observation was also seen in the CARMA cohort, where the prevalence of hypertension (65.1%), dyslipidemia (53.5%), and DM (23.3%) was lower in Spaniards with cardiovascular events. 23 These discrepancies could be related to the fact that RA patients were approximately 11 years younger in the CORRONA study and 14 years younger in the CARMA study in comparison to ours.…”

“… 23 In another multinational RA cohort, CORRONA, arterial vascular events were more commonly seen in Eastern European regions (21.3%), followed by Latin America (8.5%) and the United States (8.5%). 13 …”

“… 12 Traditional and nontraditional risk factors for arterial vascular events vary among different ethnic groups. 13 However, limited studies have been conducted in Hispanics from Latin America and the United States. Thus, the aim of this observational study was to determine the factors associated with the occurrence of arterial vascular events in a cohort of Hispanics from Puerto Rico with RA.…”

Chronic Heart Failure in Rheumatoid Arthritis Patients (Part I): Prevalence, Etiology and Pathogenesis

“…В когортном исследовании показано 30% увеличение риска госпитализации по поводу СН у пациентов с РА [17]. По данным регистра CORRONA распространенность ХСН у больных РА в Восточной Европе (треть из которых проживает в Российской Федерации) почти в 2 раза выше, чем в США [18]. При этом Фрамингемские критерии могут недооценивать ХСН с сохраненной систолической функцией левого желудочка (ЛЖ) [19], в большинстве работ не использовались критерии Европейского общества кардиологов с комбинированием клинических, эхокардиографических данных и уровня натриуретического гормона (В-типа) N-концевого пропептида (NT-proBNP) [20].…”

The incidence of type 2 diabetes mellitus and the traditional risk factors of carbohydrate metabolic disorders in patients with rheumatoid arthritis

“…По данным международного регистра СORRONA (International Registry of Longitudinal Outcomes and Associated Cardiovascular Comorbidities in Patients with Rheumatoid Arthritis), распространенность СД при РА колеблется от 8,4% в Латинской Америке и США до 12,4% в Восточной Европе и 13,5% в Индии [2]. Учитывая возраст включенных в регистр больных, можно предположить, что большая часть указанных случаев СД относится к СД 2-го типа, однако неясно, как часто эндокринное заболевание развивалось на фоне уже существующего РА, а не предшествовало ему.…”